Cargando…

POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies

Detalles Bibliográficos
Autores principales: Lee, Y, Lee, K, Park, H, Neese, M, Khan, ZM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769589/
http://dx.doi.org/10.1016/j.jval.2021.11.698
_version_ 1784635181363101696
author Lee, Y
Lee, K
Park, H
Neese, M
Khan, ZM
author_facet Lee, Y
Lee, K
Park, H
Neese, M
Khan, ZM
author_sort Lee, Y
collection PubMed
description
format Online
Article
Text
id pubmed-8769589
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-87695892022-01-20 POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies Lee, Y Lee, K Park, H Neese, M Khan, ZM Value Health Article Published by Elsevier Inc. 2022-01 2022-01-19 /pmc/articles/PMC8769589/ http://dx.doi.org/10.1016/j.jval.2021.11.698 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lee, Y
Lee, K
Park, H
Neese, M
Khan, ZM
POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies
title POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies
title_full POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies
title_fullStr POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies
title_full_unstemmed POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies
title_short POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies
title_sort posa225 comparing the us drug development, pricing, access, and reimbursement strategies for covid-19 vaccines as a potential model for novel oncology therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769589/
http://dx.doi.org/10.1016/j.jval.2021.11.698
work_keys_str_mv AT leey posa225comparingtheusdrugdevelopmentpricingaccessandreimbursementstrategiesforcovid19vaccinesasapotentialmodelfornoveloncologytherapies
AT leek posa225comparingtheusdrugdevelopmentpricingaccessandreimbursementstrategiesforcovid19vaccinesasapotentialmodelfornoveloncologytherapies
AT parkh posa225comparingtheusdrugdevelopmentpricingaccessandreimbursementstrategiesforcovid19vaccinesasapotentialmodelfornoveloncologytherapies
AT neesem posa225comparingtheusdrugdevelopmentpricingaccessandreimbursementstrategiesforcovid19vaccinesasapotentialmodelfornoveloncologytherapies
AT khanzm posa225comparingtheusdrugdevelopmentpricingaccessandreimbursementstrategiesforcovid19vaccinesasapotentialmodelfornoveloncologytherapies